ILM1D Stock Overview
Supplies specialty pharmaceutical drugs primarily in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medios AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €14.72 |
| 52 Week High | €14.72 |
| 52 Week Low | €14.72 |
| Beta | 1.07 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -14.42% |
| Change since IPO | 0.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILM1D | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | 0.8% |
| 1Y | n/a | -23.5% | 6.6% |
Return vs Industry: Insufficient data to determine how ILM1D performed against the UK Healthcare industry.
Return vs Market: Insufficient data to determine how ILM1D performed against the UK Market.
Price Volatility
| ILM1D volatility | |
|---|---|
| ILM1D Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ILM1D has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ILM1D's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 424 | Matthias Gaertner | www.medios.ag |
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases.
Medios AG Fundamentals Summary
| ILM1D fundamental statistics | |
|---|---|
| Market cap | €341.85m |
| Earnings (TTM) | €18.81m |
| Revenue (TTM) | €1.78b |
18.2x
P/E Ratio0.2x
P/S RatioIs ILM1D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILM1D income statement (TTM) | |
|---|---|
| Revenue | €1.78b |
| Cost of Revenue | €1.68b |
| Gross Profit | €108.63m |
| Other Expenses | €89.82m |
| Earnings | €18.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 6.09% |
| Net Profit Margin | 1.05% |
| Debt/Equity Ratio | 0% |
How did ILM1D perform over the long term?
See historical performance and comparison